Micron Technology Beats Q2 Earnings Estimates, Issues Strong AI-Driven Outlook 
Yen Slides Near Two-Year Low as Fed Holds Rates Amid Middle East Tensions 
Samsung Bets Big on AI-Driven Chip Demand in 2025 
OpenAI's Desktop Superapp: Unifying ChatGPT, Codex, and Browser Tools for Enterprise AI 
Bank of Japan Holds Rates Steady Amid Inflation Concerns and Yen Weakness 
Gold Prices Stabilize but Head for Worst Weekly Drop in Six Years Amid Iran War Inflation Fears 
Elon Musk Confirms SpaceX, xAI, and Tesla Will Continue Large-Scale Nvidia Chip Orders 
Japan's Major Companies Lead Strong Wage Growth for Fourth Consecutive Year 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
Super Micro Computer Shares Plunge After Co-Founder Charged in AI Chip Smuggling Case 
Elliott Investment Management Takes Activist Stake in Align Technology 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
DOJ Antitrust Chief Rejects Political Fast-Track for Paramount-Skydance Deal 
Xiaomi's AI Model "Hunter Alpha" Mistaken for DeepSeek's Next Release 
Fed Holds Rates Steady as Middle East Conflict Clouds Inflation Outlook 
Israel Defies Trump's Warning, Launches New Strikes on Iran Amid Growing Global Energy Crisis 
Oil Prices Surge Past $100 as U.S.-Israel War on Iran Threatens Global Energy Supply 
Lotte Biologics has completed the acquisition process to take over the manufacturing facility of Bristol Myers Squibb in Syracuse, New York, for $160 million. The drug manufacturing unit of the Lotte Group confirmed the deal on Tuesday, Jan. 3.
With the addition of Bristol Myers Squibb’s plant in Lotte Biologics’ property portfolio, the fifth-largest retail-chemical company in South Korea has officially jumped into the contract manufacturing business. This acquisition also comes after the Lotte Group launched Lotte Biologics, a biological CDMO (Contract Development Manufacturing Organization), in June 2022.
As per The Korea Herald, the company actually completed the takeover of the Bristol Myers Squibb facility on Dec. 31. All of its existing manufacturing contract agreements for drug production are also included in the acquisition. It was reported that these deals are worth $220 million and deliveries are to be carried out over the next three years.
The South Korean CDMO firm also revealed its plans to invest $70 million to upgrade the manufacturing facility in Syracuse. This investment will add manufacturing lines for drug substances, antibody-drug conjugates, and other drug products.
As Lotte Biologics buys Bristol Myers Squibb's manufacturing facility, it will also be creating around 70 jobs, and they will be assigned to various roles at the plant. This will be an addition to the existing BMS workforce, which is said to be 450 in number.
“Based on the successful acquisition of the Syracuse Plant, Lotte Biologics will emerge as a global CDMO that can achieve 1.5 trillion KRW in sales, a 30% operating margin, and a corporate value of 20 trillion KRW by 2030 by providing innovative medicines to patients,” Lotte Biologics’ chief executive officer, Richard Lee, said in a press release. “We will continue to grow at a rapid pace.”
The CEO further said that his goal is to successfully establish the company as a new growth engine for the Lotte Group. Lee will work on achieving this ambition by signing partnership deals with some global pharmaceutical companies and securing other bio ventures.
